Istacare 50mg/1000mg Tablet is a combination oral antidiabetic medication containing Sitagliptin 50mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active incretin hormones, which regulate glucose homeostasis by increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic action of Sitagliptin and Metformin provides effective glycemic control by targeting multiple pathophysiological defects in type 2 diabetes. Istacare is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on either agent alone or those already receiving the combination. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while rare but serious risks include lactic acidosis and pancreatitis. Regular monitoring of renal function and glycemic parameters is recommended during therapy to ensure safety and efficacy.